A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Pfizer
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AHS Cancer Control Alberta
Dana-Farber Cancer Institute
Eisai Inc.
M.D. Anderson Cancer Center
Duke University
University of Pittsburgh
St. Jude Children's Research Hospital
New Mexico Cancer Research Alliance
Sinai Hospital of Baltimore
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Samsung Medical Center